CF
VIR icon

Cantor Fitzgerald’s Vir Biotechnology VIR Stock Holding History

Cantor Fitzgerald’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-243,110
Closed -$2.16M – 308
2024
Q2 		$2.16M Buy
+243,110
New +$2.33M 0.43% 47

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Cantor Fitzgerald's VIR Position: Q3 2024 in Review

Cantor Fitzgerald sold out of Vir Biotechnology (VIR) in Q3 2024, closing a stake of 243,110 shares — an estimated $2.16M sold.

Cantor Fitzgerald first reported a position in VIR in Q2 2024 and held it in 1 quarter. The position peaked at $2.16M in Q2 2024. 197 funds tracked by Wall St. Rank hold VIR as of Q3 2024.

  • Cantor Fitzgerald reported no remaining Vir Biotechnology position as of Q3 2024 after selling out during the quarter.
  • Cantor Fitzgerald sold 243,110 Vir Biotechnology shares in Q3 2024, an estimated $2.16M.
  • Cantor Fitzgerald first reported a position in Vir Biotechnology in Q2 2024 and held it in 1 quarter.
  • Cantor Fitzgerald's Vir Biotechnology position peaked at $2.16M in Q2 2024.
  • 197 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2024.

Based on Cantor Fitzgerald's 13F filing for Q3 2024, filed 14 Nov 2024.